tiprankstipranks
Blurbs

Can-Fite BioPharma (CANF) Receives a Buy from H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Can-Fite BioPharma (CANFResearch Report), with a price target of $5.00. The company’s shares closed last Tuesday at $1.24.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 27.9% and a 38.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Citius Pharmaceuticals, and Aridis Pharmaceuticals.

Can-Fite BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $7.00, implying a 455.6% upside from current levels. In a report issued on March 25, Dawson James also maintained a Buy rating on the stock with a $9.00 price target.

See today’s best-performing stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn’s disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.

Read More on CANF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed